(Q36297527)

13 August 2017

1 reference

title

The pharmacologic modulation of the hypermetabolic response to burns (English)

1 reference

13 August 2017

Clifford T Pereira

1

1 reference

13 August 2017

David N Herndon

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

39

1 reference

13 August 2017

page(s)

245-261

1 reference

Persistence of muscle catabolism after severe burn.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Insulin Response to Glucose in Hypermetabolic Burn Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

A great constitutional disturbance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Catecholamines: mediator of the hypermetabolic response to thermal injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effect of severe burn injury on substrate cycling by glucose and fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

The metabolic basis of the increase of the increase in energy expenditure in severely burned patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Influence of the burn wound on local and systemic responses to injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Dynamics of the protein metabolic response to burn injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Growth delay in postburn pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Determinants of skeletal muscle catabolism after severe burn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Allograft is superior to topical antimicrobial therapy in the treatment of partial-thickness scald burns in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Biosynthetic skin substitute versus frozen human cadaver allograft for temporary coverage of excised burn wounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Artificial Dermis for Major Burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Mechanism of prevention of postburn hypermetabolism and catabolism by early enteral feeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Enteral feeding in burn hypermetabolism: nutritional and metabolic effects of different levels of calorie and protein intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Does Increased Evaporative Water Loss Cause Hypermetabolism in Burned Patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Growth hormone down-regulation of Interleukin-1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Increased expression of insulin-like growth factor-I in serum and liver after recombinant human growth hormone administration in thermally injured rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

The effect of short-term growth hormone treatment on growth and energy expenditure in burned children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effects of recombinant human growth hormone on donor-site healing in severely burned children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effect of growth hormone therapy in burn patients on conservative treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Increased mortality associated with growth hormone treatment in critically ill adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Growth hormone treatment in pediatric burns: a safe therapeutic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Insulin-like growth factor 1 (IGF-1) in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Insulin therapy in burn patients does not contribute to hepatic triglyceride production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Chronic tissue insulin resistance following hemorrhagic shock.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Testosterone administration in severe burns ameliorates muscle catabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Short-term oxandrolone administration stimulates net muscle protein synthesis in young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Anabolic effects of oxandrolone after severe burn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effects of long-term oxandrolone administration in severely burned children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effect of exogenous growth hormone and exercise on lean mass and muscle function in children with burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Cold stress response in patients with severe burns after beta-blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Prolonged use of propranolol safely decreases cardiac work in burned children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Propranolol diminishes extremity blood flow in burned patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Propranolol decreases splanchnic triacylglycerol storage in burn patients receiving a high-carbohydrate diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Reversal of catabolism by beta-blockade after severe burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Gene expression profiles and protein balance in skeletal muscle of burned children after beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Current pharmacotherapy for the treatment of severe burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

Reassessing caloric requirements in pediatric burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2005.05.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YASU.2005.05.005

1 reference

13 August 2017

1 reference